The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy
Pharma & Human Health

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy

SEP 24, 2024
Abolis Biotechnologies Secures €35M to Accelerate R&D in Innovative Biomanufacturing & Microbiome Solutions
Finance

Abolis Biotechnologies Secures €35M to Accelerate R&D in Innovative Biomanufacturing & Microbiome Solutions

SEP 19, 2024
ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®
Gastrointestinal

ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®

SEP 16, 2024
32 Biosciences Emerges from Stealth Mode with New Approach to Gut Microbiome Medicine
Finance

32 Biosciences Emerges from Stealth Mode with New Approach to Gut Microbiome Medicine

SEP 13, 2024
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results 
Pharma & Human Health

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results 

SEP 12, 2024
dsm-firmenich secures UK and EU approvals for 3-FL and LNFP-I/2′-FL HMO ingredients
Pharma & Human Health

dsm-firmenich secures UK and EU approvals for 3-FL and LNFP-I/2′-FL HMO ingredients

SEP 12, 2024
Viome Raises $25M To Launch Diagnostic Division
Finance

Viome Raises $25M To Launch Diagnostic Division

SEP 11, 2024
Lallemand inaugurates new research and development laboratories
Finance

Lallemand inaugurates new research and development laboratories

SEP 5, 2024
IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality
Clinical & Manufacturing

IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality

SEP 4, 2024
ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market
Biotics and Supplements

ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market

SEP 2, 2024
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
Clinical & Manufacturing

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus

SEP 1, 2024